Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15081285 | 0.86 | ALDH1A1 (0.45) | ALDH1A1LMNAKMT2AMEN1PDGFRB | |
| SCHEMBL913705 | 0.86 | PDGFRB (0.46) | ALDH1A1KMT2AMEN1PDGFRBFGFR1 | |
| SCHEMBL30353758 | 0.86 | ALDH1A1 (0.45) | ALDH1A1LMNAKMT2AMEN1PDGFRB | |
| SCHEMBL24723054 | 0.84 | PDGFRB (0.45) | ALDH1A1LMNAKMT2AMEN1NPSR1 | |
| SCHEMBL5628047 | 0.84 | KMT2A (0.56) | ALDH1A1LMNAKMT2AMEN1NPSR1 | |
| SCHEMBL2522809 | 0.84 | PDGFRB (0.50) | ALDH1A1LMNAKMT2AMEN1NPSR1 | |
| SCHEMBL357183 | 0.83 | SIRT6 (0.44) | ALDH1A1LMNAKMT2AMEN1PDGFRB | |
| SCHEMBL16935287 | 0.83 | PDGFRB (0.44) | ALDH1A1KMT2AMEN1PDGFRBFGFR1 | |
| SCHEMBL25249572 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNAKMT2AMEN1PDGFRB | |
| SCHEMBL1462927 | 0.83 | TDP1 (0.47) | LMNAKMT2AMEN1PDGFRBFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283787-A1 | METHOD FOR NON-ENZYMATIC COMBINATION OF NUCLEIC ACID CHAINS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2017-10-05 | — | — | US | disclosed |
| US-20170283787-A1 | METHOD FOR NON-ENZYMATIC COMBINATION OF NUCLEIC ACID CHAINS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2017-10-05 | — | — | US | disclosed |
| EP-3187584-A1 | METHOD FOR NON-ENZYMATIC COMBINATION OF NUCLEIC ACID CHAINS | Japan Science and Technology Agency (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| CN-1735592-A | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LTD (GB) | 2006-02-15 | — | — | CN | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| WO-2005113525-A1 | N, N’-SUBSTITUTED-1,3-DIAMINO-2-OXOPROPANE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND USE | GLAXO GROUP LIMITED (GB) | 2005-12-01 | — | — | WO | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283787-A1 | METHOD FOR NON-ENZYMATIC COMBINATION OF NUCLEIC ACID CHAINS | RNGTT, POLRMT, DNTT | ALDH1A1 1261/4885LMNA 1347/4885KMT2A 1835/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | ALDH1A1 3102/4885LMNA 1062/4885KMT2A 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.